Roche has been attempting to develop an Alzheimer's drug for some time, and its first attempts with two other anti-amyloid antibodies – crenezumab and gantenerumab – ended in failure.

Apellis is expecting decisions on the drug form regulators in the UK, Switzerland, Canada, and Australia early next year. Photo by Nathan Dumlao on Unsplash. Image. Phil Taylor.